Not affiliated with or endorsed by AACR.
April 25-30, 2025
McCormick Place Convention Center
Chicago, IL
Booth #400
Connect with Caris Life Sciences at AACR 2025
Join Caris Life Sciences® at the upcoming American Association for Cancer Research® (AACR) Annual Meeting in Chicago, IL. Visit our team at booth #400 to discover the latest innovations in precision medicine and learn how our products and services are leading the molecular revolution.
Abstracts and Poster Presentations
In collaboration with Caris Precision Oncology Alliance™ (POA) members, we are continually developing insights into a broad range of biomarkers and tumor types. As a result, this year’s American Association for Cancer Research (AACR) annual meeting abstracts cover an extensive set of precision medicine insights across glioblastoma and lung, gastric, gastro-esophageal, colorectal, pancreatic, bladder, ovarian, and cervical cancers. In total, Caris and our POA collaborators will present 14 abstracts, including two oral presentations and twelve posters.
Oral Presentations:
Pre-operative abemaciclib in localized cisplatin-ineligible MIBC with tissue and ctDNA molecular response validation (CLONEVO)
(Abstract: CT127)
Monday, April 28; 2:50 PM – 3:00 PM CDT
Kinase fusion landscape of pancreatic cancer
(Abstract: 3781)
Monday, April 28; 3:40 PM – 3:55 PM CDT
Schedule a Meeting
Products at a glance
Caris Assure
Whole Exome and Whole Transcriptome Sequencing from blood. This revolutionary, pan-cancer assay utilizes a novel circulating Nucleic Acid Sequencing (cNAS) approach. With deep molecular insights from a minimally invasive blood sample, Caris Assure™ delivers uncompromising reliability and performance to inform personalized treatment decisions to help improve patient outcomes.
MI Profile
MI Profile™ comprehensive testing delivers whole exome sequencing (WES – DNA) and whole transcriptome sequencing (WTS – RNA) for 23,000+ genes, as well as protein analysis and AI-predictive algorithms. The test is designed to reveal a complete molecular blueprint that can guide more precise and individualized treatment decisions that help improve patient outcomes.
Caris Molecular AI
With one of the largest, multi-modal databases of combined molecular and clinical outcomes data in the world, Caris applies highly sophisticated AI bioinformatics and machine learning capabilities on this massive database to create novel, clinically relevant solutions to classify cancer at the molecular level and predict patient response in ways never before possible.
Caris Abstracts and Presentation Schedule
Caris’ strong presence at AACR 2025 demonstrates the clinical value of comprehensive molecular profiling and our commitment to transforming lives through research. Download the abstracts and presentation schedule, including a full list of summaries highlighting the research presented at AACR 2025.
Discover
More
Personalized Treatment Starts Here
Understanding cancer at the molecular level can lead to better treatment options. Caris molecular profiling includes whole exome and whole transcriptome sequencing of tissue and blood, plus protein analysis and other testing options for tissue specimens. Paired with molecular AI tools, Caris comprehensive molecular profiling is focused on helping cancer patients today and tomorrow.
Expert Scientific and Clinical Support
Caris’ healthcare provider services help put precision medicine into practice. Deep molecular insights enable physicians to navigate among therapies with potential benefit, identify therapies that may not have been considered, determine drugs unlikely to provide benefit (avoiding unnecessary toxicities and costs) and match patients to clinical trials.